JP6522908B2 - Composition for external use - Google Patents
Composition for external use Download PDFInfo
- Publication number
- JP6522908B2 JP6522908B2 JP2014171807A JP2014171807A JP6522908B2 JP 6522908 B2 JP6522908 B2 JP 6522908B2 JP 2014171807 A JP2014171807 A JP 2014171807A JP 2014171807 A JP2014171807 A JP 2014171807A JP 6522908 B2 JP6522908 B2 JP 6522908B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ceramide
- weight
- external use
- ceramides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 174
- 229940106189 ceramide Drugs 0.000 claims description 85
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 75
- 150000001783 ceramides Chemical class 0.000 claims description 52
- -1 polyoxyethylene Polymers 0.000 claims description 40
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 31
- 229940048864 ceramide 1 Drugs 0.000 claims description 31
- 229940044176 ceramide 3 Drugs 0.000 claims description 31
- 229940099417 ceramide 2 Drugs 0.000 claims description 30
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 26
- 239000000194 fatty acid Substances 0.000 claims description 26
- 229930195729 fatty acid Natural products 0.000 claims description 26
- 150000004665 fatty acids Chemical class 0.000 claims description 24
- 150000005846 sugar alcohols Polymers 0.000 claims description 24
- 239000004359 castor oil Substances 0.000 claims description 23
- 239000006210 lotion Substances 0.000 claims description 23
- 235000019438 castor oil Nutrition 0.000 claims description 22
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 21
- 229910052783 alkali metal Inorganic materials 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 description 36
- 239000002244 precipitate Substances 0.000 description 35
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 33
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 33
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 33
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 33
- 238000009472 formulation Methods 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 16
- 125000002252 acyl group Chemical group 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000002736 nonionic surfactant Substances 0.000 description 14
- 238000001556 precipitation Methods 0.000 description 14
- 210000000434 stratum corneum Anatomy 0.000 description 13
- 239000008213 purified water Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000001509 sodium citrate Substances 0.000 description 8
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 8
- 229940038773 trisodium citrate Drugs 0.000 description 8
- 235000019263 trisodium citrate Nutrition 0.000 description 8
- 230000001629 suppression Effects 0.000 description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 6
- 239000005642 Oleic acid Substances 0.000 description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 4
- 229940033329 phytosphingosine Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- LRPSCNBFQVBIDI-JNTOXOLQSA-N (20R,21S,22R)-20-amino-19,21,22-trihydroxyhexatriacontan-18-one Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)C(O)[C@H](N)[C@H](O)[C@H](O)CCCCCCCCCCCCCC LRPSCNBFQVBIDI-JNTOXOLQSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- LVOGXJMCDAOKSQ-UHFFFAOYSA-N 10-oxo-10-propan-2-yloxydecanoic acid Chemical compound CC(C)OC(=O)CCCCCCCCC(O)=O LVOGXJMCDAOKSQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- JPWUIQIFCDAWQX-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(O)CO JPWUIQIFCDAWQX-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
- KZTJQXAANJHSCE-OIDHKYIRSA-N N-octodecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC KZTJQXAANJHSCE-OIDHKYIRSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002444 monopotassium citrate Substances 0.000 description 1
- 235000015861 monopotassium citrate Nutrition 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- WKZJASQVARUVAW-UHFFFAOYSA-M potassium;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].OC(=O)CC(O)(C(O)=O)CC([O-])=O WKZJASQVARUVAW-UHFFFAOYSA-M 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940077082 red pepper extract Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、セラミド1〜3の中の2種以上のセラミドと水を含みながらも、経時的な析出物の生成が抑制され、優れた製剤安定性を備える外用組成物に関する。 The present invention relates to an external use composition having excellent formulation stability in which the formation of precipitates with time is suppressed while containing two or more types of ceramide of ceramides 1 to 3 and water.
乾燥、紫外線等の種々の環境因子や、加齢に伴う皮膚の老化、アトピー性病変等により角質層のバリア機能や保湿機能が低下すると、肌荒れ、乾燥肌等の皮膚症状が生じることが知られており、肌を健全な状態するためには、角質層のバリア機能及び保湿機能を適正に保つことが重要である。 It is known that when the barrier function or moisturizing function of the stratum corneum decreases due to various environmental factors such as dryness and ultraviolet rays, aging of the skin with aging, and atopic lesions, skin symptoms such as rough skin and dry skin occur. In order to keep the skin healthy, it is important to keep the barrier function and the moisturizing function of the stratum corneum appropriate.
角質層は、主に、角層細胞及びラメラ構造を形成した細胞間脂質からから構成されており、バリア機能や保湿機能には、角層細胞間脂質のラメラ構造が重要な役割を担っている。また、角層細胞間脂質は、その約50%がセラミドによって構成されており、角質層中のセラミド含量が低下すると、バリア機能や保湿機能が低下することが知られている。そこで、従来、角質層中のセラミドを補うことにより角質層の機能を維持させる目的で、セラミドを配合した外用組成物が開発されている。しかしながら、セラミドは、結晶性が高いという特有の性質があり、外用組成物の基材(特に水)に溶解し難く、一旦溶解させても保存時に析出するという欠点がある。 The stratum corneum is mainly composed of stratum corneum cells and intercellular lipids forming a lamellar structure, and the lamellar structure of stratum corneum intercellular lipids plays an important role in the barrier function and the moisturizing function. . In addition, about 50% of the stratum corneum intercellular lipid is composed of ceramide, and it is known that when the content of ceramide in the stratum corneum decreases, the barrier function and the moisturizing function decrease. Then, the external composition which mix | blended ceramide is conventionally developed in order to maintain the function of a stratum corneum by supplementing the ceramide in a stratum corneum. However, ceramide has a characteristic property of high crystallinity, is difficult to be dissolved in the base material (particularly water) of the composition for external use, and has a disadvantage that it precipitates during storage even if it is once dissolved.
従来、セラミドの析出を抑制する製剤技術について種々検討されている。例えば、特許文献1には、セラミド類と共にアルキロイル乳酸エステルを配合して乳化させることによって、セラミドの経時的な析出を抑制できることが開示されている。また、特許文献2には、セラミドと共に、アルキロイル乳酸及び/又はその塩、並びにグリセリン及び/又は重合度2以上のポリグリセリン脂肪酸エステルとを組み合わせて配合することによって、セラミドの経時的な析出を抑制できることが開示されている。更に、特許文献3には、セラミドと共に、炭素数12〜24の長鎖脂肪酸、非イオン界面活性剤、及び水を配合することによって、セラミドを高濃度(1.0〜5.0重量%)で含有しても、透明で安定性に優れた水性透明性組成物が得られることを開示している。 Heretofore, various investigations have been made on formulation techniques for suppressing the precipitation of ceramide. For example, Patent Document 1 discloses that the precipitation with time of ceramide can be suppressed by blending and emulsifying an alkyloyl lactic acid ester with ceramides. Further, in Patent Document 2, the temporal precipitation of ceramide is suppressed by blending together with ceramide an alkyloyl lactic acid and / or a salt thereof, and glycerin and / or a polyglycerin fatty acid ester having a degree of polymerization of 2 or more. What can be done is disclosed. Furthermore, Patent Document 3 contains a high concentration of ceramide (1.0 to 5.0% by weight) by blending a long-chain fatty acid having 12 to 24 carbon atoms, a nonionic surfactant, and water together with ceramide. It is disclosed that a transparent, highly stable aqueous transparent composition can be obtained even when containing
角質層内には11種類のセラミド(セラミド1〜5、6−1、6−2、及び7〜10)が存在しており、セラミドの種類毎に担っている機能も異なっていることが知られている。また、2種以上のセラミドを組み合わせて製剤化すると、その組み合わせ態様によっては、セラミドの溶解性が高まって析出し難くなる場合があれば、逆にセラミドの溶解性が低下してより析出が一層生じ易くなる場合もあることが知られている。 It is known that 11 types of ceramides (ceramides 1 to 5, 6-1, 6-2, and 7 to 10) exist in the stratum corneum, and the function of each type of ceramide is also different. It is done. In addition, when two or more types of ceramides are combined and formulated, depending on the combination mode, if the solubility of ceramides may increase and it may be difficult to precipitate, conversely, the solubility of ceramides may decrease to further precipitate more. It is known that it may be easy to occur.
一方、セラミド1は、主にバリア機能を担っており、セラミド2及び3は主に保湿機能を担っており、セラミド1〜3は角質層において特に重要な役割を果たしていることが知られている。そのため、角質層へのセラミドの補給を目的とする外用組成物では、セラミド1〜3の中の2種以上を配合することが有効になる。しかしながら、セラミド1〜3の内、2種以上を組み合わせて製剤化すると、セラミドの溶解性が更に低下し、より一層析出し易くなり、製剤安定性が損なわれることが分かっている(後記する参考例1〜3参照)。そのため、特許文献1〜3で開示されている製剤技術でも、セラミド1〜3の内、2種以上を組み合わせた場合には、セラミドの析出抑制という点では満足できるものではない。 On the other hand, ceramide 1 is mainly responsible for the barrier function, ceramides 2 and 3 mainly for the moisturizing function, and ceramides 1 to 3 are known to play an especially important role in the stratum corneum . Therefore, in the externally applied composition for the purpose of replenishing ceramide to the stratum corneum, it is effective to blend two or more of ceramides 1 to 3. However, it has been found that when two or more of ceramides 1 to 3 are combined and formulated, the solubility of ceramide is further reduced, the precipitation is further facilitated, and the formulation stability is impaired (described later) Reference Examples 1 to 3). Therefore, even in the formulation techniques disclosed in Patent Documents 1 to 3, when two or more of ceramides 1 to 3 are combined, it is not satisfactory in terms of suppression of precipitation of ceramide.
そこで、本発明の目的は、セラミド1〜3の中の2種以上のセラミドと水を含みながらも、経時的な析出物の生成が抑制され、優れた製剤安定性を備える外用組成物を提供することである。 Therefore, an object of the present invention is to provide an external composition having excellent formulation stability, in which the formation of precipitates with time is suppressed while containing two or more of ceramides of ceramides 1 to 3 and water. It is to be.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、セラミド1〜3の中の2種以上のセラミドと水と共に、高級脂肪酸、非イオン性界面活性剤、多価アルコール、並びにクエン酸及び/又はそのアルカリ金属塩を組み合わせて配合することによって、経時的な析出物の生成を抑制でき、優れた製剤安定性を備える外用組成物が得られることを見出した。本発明は、かかる知見に基づいて更に検討を重ねることにより完成したものである。
即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. (A)セラミド1、セラミド2及びセラミド3よりなる群から選択される少なくとも2種のセラミド、(B)高級脂肪酸、(C)非イオン性界面活性剤、(D)多価アルコール、(E)クエン酸及び/又はそのアルカリ金属塩、並びに(F)水を含有することを特徴とする、外用組成物。
項2. 前記(A)成分が、セラミド2と、セラミド1及び/又はセラミド3との組み合わせである、項1に記載の外用組成物。
項3. 前記(C)成分が、ポリオキシエチレン硬化ヒマシ油である、項1又は2に記載の外用組成物。
項4. 前記(E)成分が、クエン酸のナトリウム塩である、項1〜3のいずれかに記載の外用組成物。
項5. 前記(A)成分が総量で0.000001〜0.05重量%含まれる、項1〜4のいずれかに記載の外用組成物。
項6. 前記(B)成分が0.001〜0.1重量%含まれる、項1〜5のいずれかに記載の外用組成物。
項7. 前記(C)成分が0.01〜0.5重量%含まれる、項1〜6のいずれかに記載の外用組成物。
項8. セラミド2の1重量部当たり、セラミド1が0.00001〜10000重量部、及び/又はセラミド3が0.00001〜10000重量部含まれる、項2〜7のいずれかに記載の外用組成物。
項9. 化粧料である、項1〜8のいずれかに記載の外用組成物。
項10. ローションである、項1〜9のいずれかに記載の外用組成物。
The inventors of the present invention conducted intensive studies to solve the above problems, and found that higher fatty acids, nonionic surfactants, polyhydric alcohols, and citric acid, together with two or more of ceramides of ceramides 1 to 3 and water. By combining and combining an acid and / or an alkali metal salt thereof, it has been found that the formation of precipitates with time can be suppressed, and an external use composition having excellent formulation stability can be obtained. The present invention has been completed by further studies based on such findings.
That is, the present invention provides the invention of the aspects listed below.
Item 1. (A) at least two ceramides selected from the group consisting of ceramide 1, ceramide 2 and ceramide 3, (B) higher fatty acid, (C) nonionic surfactant, (D) polyhydric alcohol, (E) An externally applied composition comprising citric acid and / or an alkali metal salt thereof, and (F) water.
Item 2. The composition for external use according to item 1, wherein the component (A) is a combination of ceramide 2 and ceramide 1 and / or ceramide 3.
Item 3. The composition for external use according to item 1 or 2, wherein the component (C) is polyoxyethylene hydrogenated castor oil.
Item 4. The composition for external use according to any one of Items 1 to 3, wherein the component (E) is a sodium salt of citric acid.
Item 5. The composition for external use according to any one of Items 1 to 4, wherein the total amount of the component (A) is 0.000001 to 0.05% by weight.
Item 6. The composition for external use according to any one of Items 1 to 5, wherein the component (B) is contained in an amount of 0.001 to 0.1% by weight.
Item 7. The composition for external use according to any one of Items 1 to 6, wherein the component (C) is contained in 0.01 to 0.5% by weight.
Item 8. The composition for external use according to any one of Items 2 to 7, wherein 0.00001 to 10000 parts by weight of Ceramide 1 and / or 0.00001 to 10000 parts by weight of Ceramide 3 are contained per 1 part by weight of Ceramide 2.
Item 9. The composition for external use according to any one of Items 1 to 8, which is a cosmetic.
Item 10. The composition for external use according to any one of Items 1 to 9, which is a lotion.
本発明の外用組成物によれば、セラミド1〜3の中の2種以上と水を含んでいながらも、経時的な析出物の生成を抑制でき、優れた製剤安定性を備えることができる。また、本発明の外用組成物では、セラミド1〜3の中の2種以上と水を含んでいても、これらのセラミドの溶解性が向上しており、これらのセラミドを0.01〜0.05重量%という高含有量で配合することもできるので、これらのセラミドに基づく有益な効果(保湿、肌荒れ改善、敏感肌の解消、皮膚老化の防止等)をより効果的に享受させ得る外用組成物の提供も可能になる。 According to the composition for external use of the present invention, although containing two or more of ceramides 1 to 3 and water, the formation of precipitates with time can be suppressed, and excellent formulation stability can be provided. . Further, in the composition for external use of the present invention, even if two or more of ceramides 1 to 3 and water are contained, the solubility of these ceramides is improved, and these ceramides are preferably 0.01 to 0. Since the composition can be formulated at a high content of 05% by weight, an external composition that can more effectively enjoy the beneficial effects (moisturizing, rough skin improvement, elimination of sensitive skin, prevention of skin aging, etc.) based on these ceramides. It also becomes possible to provide things.
本発明の外用組成物は、(A)セラミド1、セラミド2及びセラミド3よりなる群から選択される少なくとも2種のセラミド、(B)高級脂肪酸、(C)非イオン性界面活性剤、(D)多価アルコール、(E)クエン酸及び/又はそのアルカリ金属塩、並びに(F)水を含有することを特徴とする。以下、本発明の外用組成物について詳述する。 The composition for external use of the present invention comprises (A) at least two ceramides selected from the group consisting of ceramide 1, ceramide 2 and ceramide 3, (B) higher fatty acid, (C) nonionic surfactant, (D) A) a polyhydric alcohol, (E) citric acid and / or an alkali metal salt thereof, and (F) water. Hereinafter, the composition for external use of the present invention will be described in detail.
(A)セラミド
本発明の外用組成物は、セラミド1、セラミド2及びセラミド3の中から2種以上のセラミドを含有する。本発明の外用組成物では、セラミド1〜3の中の2種以上併用して水と共に製剤化しても、後述する(B)〜(E)成分を一体として含有させることにより、経時的な析出物の生成を抑制することが可能になる。
(A) Ceramide The composition for external use of the present invention contains two or more kinds of ceramides from ceramide 1, ceramide 2 and ceramide 3. In the composition for external use according to the present invention, even when two or more of ceramides 1 to 3 are used in combination to formulate with water, temporally precipitates by integrally containing the components (B) to (E) described later. It becomes possible to suppress the generation of objects.
(セラミド1)
本発明で使用されるセラミド1としては、具体的には、N−(ω−アシルオキシ−アシル)フィトスフィンゴシン、及びN−(ω−アシルオキシ−アシル)スフィンゴシンが挙げられる。
(Ceramide 1)
Specific examples of ceramide 1 used in the present invention include N- (ω-acyloxy-acyl) phytosphingosine and N- (ω-acyloxy-acyl) sphingosine.
セラミド1を構成するアシルオキシアシル基において、フィトスフィンゴシン又はスフィンゴシンにアミド結合で連結している側のアシル基(以下、「アミド結合側のアシル基」とも表記する)の炭素数については、特に制限されないが、例えば20〜38程度、好ましくは20〜34、より好ましくは24〜30、更に好ましくは26〜27、特に好ましくは27が挙げられる。また、アミド結合側のアシル基は、直鎖状又は分岐状のいずれであってもよく、更に飽和又は不飽和のいずれであってもよいが、直鎖状で飽和のものが好ましい。 In the acyloxyacyl group constituting ceramide 1, the carbon number of the acyl group on the side linked to phytosphingosine or sphingosine via an amide bond (hereinafter also referred to as "acyl group on the amide bond side") is not particularly limited. For example, about 20 to 38, preferably 20 to 34, more preferably 24 to 30, still more preferably 26 to 27, and particularly preferably 27. The acyl group on the amide bond side may be either linear or branched, and may be saturated or unsaturated, but is preferably linear and saturated.
また、セラミド1を構成するアシルオキシアシル基において、アミド結合側のアシル基とエステル結合を介して連結しているアシル基(以下、「エステル結合側のアシル基」とも表記する)の炭素数については、特に制限されないが、例えば12〜38程度、好ましくは14〜30、より好ましくは16〜28、更に好ましくは16〜20、特に好ましくは18が挙げられる。また、エステル結合側のアシル基は、直鎖状又は分岐状のいずれであってもよく、更に飽和又は不飽和のいずれであってもよいが、直鎖状で飽和のものが好ましい。更に、エステル結合側のアシル基にはヒドロキシル基が含まれていてもよい。 In the acyloxyacyl group constituting ceramide 1, the carbon number of the acyl group linked to the acyl group on the amide bond side via an ester bond (hereinafter also referred to as "acyl group on the ester bond") is Although not particularly limited, for example, about 12 to 38, preferably 14 to 30, more preferably 16 to 28, more preferably 16 to 20, and particularly preferably 18 are mentioned. The acyl group on the ester bond side may be either linear or branched, and may be saturated or unsaturated, but is preferably linear and saturated. Furthermore, the acyl group on the ester bond side may contain a hydroxyl group.
これらのセラミド1は1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These ceramides 1 may be used alone or in combination of two or more.
セラミド1の中でも、好ましくはN−(ω−アシルオキシ−アシル)フィトスフィンゴシンが挙げられる。 Among ceramides 1, N- (ω-acyloxy-acyl) phytosphingosine is preferably mentioned.
(セラミド2)
本発明で使用されるセラミド2としては、具体的には、N−アシルジヒドロスフィンゴシン、及びN−アシルスフィンゴシンが挙げられる。
(Ceramide 2)
Specific examples of ceramide 2 used in the present invention include N-acyl dihydrosphingosine and N-acyl sphingosine.
セラミド2を構成するアシル基の炭素数については、特に制限されないが、例えば12〜38程度、好ましくは14〜30、より好ましくは16〜28、更に好ましくは16〜24、特に好ましくは18が挙げられる。 The carbon number of the acyl group constituting the ceramide 2 is not particularly limited, but, for example, about 12 to 38, preferably 14 to 30, more preferably 16 to 28, more preferably 16 to 24, particularly preferably 18 Be
また、セラミド2を構成するアシル基は、直鎖状又は分岐状のいずれであってもよく、更に飽和又は不飽和のいずれであってもよいが、直鎖状で飽和のものが好ましい。また、セラミド2を構成するアシル基は、ヒドロキシル基が含まれていてもよいが、ヒドロキシル基が含まれていないアシル基であることが好ましい。 The acyl group constituting the ceramide 2 may be either linear or branched, and may be either saturated or unsaturated, but is preferably linear and saturated. Moreover, although the acyl group which comprises ceramide 2 may contain a hydroxyl group, it is preferable that it is an acyl group which does not contain a hydroxyl group.
これらのセラミド2は1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These ceramides 2 may be used alone or in combination of two or more.
セラミド2の中でも、好ましくはN−アシルジヒドロスフィンゴシンが挙げられる。 Among ceramides 2, preferably N-acyl dihydrosphingosine is mentioned.
(セラミド3)
本発明で使用されるセラミド3としては、具体的には、N−アシルフィトスフィンゴシンが挙げられる。
(Ceramide 3)
Specifically as ceramide 3 used by this invention, N-acyl phytosphingosine is mentioned.
セラミド3を構成するアシル基の炭素数については、特に制限されないが、例えば12〜38程度、好ましくは14〜30、より好ましくは16〜28、更に好ましくは16〜24、特に好ましくは18が挙げられる。 The carbon number of the acyl group constituting the ceramide 3 is not particularly limited, but for example, about 12 to 38, preferably 14 to 30, more preferably 16 to 28, more preferably 16 to 24, particularly preferably 18 Be
また、セラミド3を構成するアシル基は、直鎖状又は分岐状のいずれであってもよく、更に飽和又は不飽和のいずれであってもよいが、直鎖状で飽和のものが好ましい。また、セラミド3を構成するアシル基は、ヒドロキシル基が含まれていてもよいが、ヒドロキシル基が含まれていないアシル基であることが好ましい。 The acyl group constituting the ceramide 3 may be linear or branched, and may be saturated or unsaturated, but is preferably linear or saturated. Moreover, although the acyl group which comprises ceramide 3 may contain a hydroxyl group, it is preferable that it is an acyl group which does not contain a hydroxyl group.
(セラミド1〜3の組み合わせ態様)
本発明の外用組成物では、セラミド1〜3の中から2種以上を組み合わせて使用する。本発明の外用組成物において、セラミド1〜3の組み合わせ態様については、特に制限されず、セラミド1とセラミド2の組み合わせ、セラミド1とセラミド3の組み合わせ、セラミド2とセラミド3の組み合わせ、セラミド1とセラミド2とセラミド3の組み合わせのいずれであってもよい。特に、従来技術では、セラミド2と、セラミド1及び/又は3とを組み合わせた場合、とりわけセラミド1とセラミド2とセラミド3とを組み合わせた場合には、セラミドの溶解性がより一層低下して、経時的な析出物の生成が顕著になるという問題点があるが、本発明では、このような従来技術の問題点を解消でき、経時的な析出物の生成を効果的に抑制することが可能になっている。このような本発明の効果に鑑みれば、セラミド1〜3の組み合わせ態様として、好ましくはセラミド2と、セラミド1及び/又は3とを組み合わせ、更に好ましくはセラミド1とセラミド2とセラミド3の組み合わせが挙げられる。
(A combination mode of ceramides 1 to 3)
In the composition for external use of the present invention, two or more of ceramides 1 to 3 are used in combination. In the composition for external use of the present invention, the combination mode of ceramides 1 to 3 is not particularly limited, and a combination of ceramide 1 and ceramide 2, a combination of ceramide 1 and ceramide 3, a combination of ceramide 2 and ceramide 3, ceramide 1 and ceramide 3 Any combination of ceramide 2 and ceramide 3 may be used. In particular, in the prior art, when ceramide 2 is combined with ceramide 1 and / or 3, especially when ceramide 1 is combined with ceramide 2 and ceramide 3, the solubility of ceramide is further reduced, Although there is a problem that the formation of precipitates with time becomes remarkable, in the present invention, such problems of the prior art can be solved, and the generation of precipitates with time can be effectively suppressed. It has become. In view of the effects of the present invention, the combination of ceramides 1 to 3 is preferably a combination of ceramide 2 and ceramide 1 and / or 3 and more preferably a combination of ceramide 1 to ceramide 2 and ceramide 3 It can be mentioned.
(セラミド1〜3の含有量・比率)
本発明の外用組成物において、セラミド1〜3の含有量については、当該外用組成物の製剤形態等に応じて適宜設定すればよいが、例えば、セラミド1〜3の総量が0.000001〜0.05重量%が挙げられる。また、一般的に、セラミド1〜3が高含有量である場合には、外用組成物において経時的な析出物の生成が顕著になる傾向があるが、本発明の外用組成物では、セラミド1〜3が0.01重量%以上という高含有量で含まれていても、経時的な析出物の生成を効果的に抑制することができる。このような本発明の効果に鑑みれば、本発明の外用組成物におけるセラミド1〜3の含有量として、好ましくは0.00001〜0.05重量%、より好ましくは0.01〜0.05重量%が挙げられる。
(Content and ratio of ceramides 1 to 3)
In the composition for external use of the present invention, the content of ceramides 1 to 3 may be appropriately set according to the formulation form of the composition for external use, etc. For example, the total amount of ceramides 1 to 3 is 0.000001 to 0 There may be .05% by weight. In general, when the content of ceramides 1 to 3 is high, formation of precipitates with time tends to be remarkable in the composition for external use, but in the composition for external use of the present invention, ceramide 1 Even when .about.3 is contained at a high content of 0.01% by weight or more, the formation of precipitates with time can be effectively suppressed. In view of such effects of the present invention, the content of ceramides 1 to 3 in the composition for external use of the present invention is preferably 0.00001 to 0.05% by weight, more preferably 0.01 to 0.05% by weight. % Is listed.
より具体的には、セラミド1を含有させる場合、本発明の外用組成物におけるセラミド1の含有量の下限としては、0.0000001重量%、より好ましくは0.000001重量%、更に好ましくは0.00001重量%が挙げられる。また、セラミド1の含有量の上限としては0.03重量%、好ましくは0.01重量%、より好ましくは0.0001重量%が挙げられる。セラミド2を含有させる場合、本発明の外用組成物におけるセラミド2の含有量の下限としては、0.0000005重量%、より好ましくは0.0001重量%、より好ましくは0.001重量%、更に好ましくは0.01重量%が挙げられる。また、セラミド2の含有量の上限としては、0.049重量%、好ましくは0.03重量%が挙げられる。セラミド3を含有させる場合、本発明の外用組成物におけるセラミド3の含有量の下限としては、0.0000001重量%、好ましくは0.000001重量%、より好ましくは0.00001重量%が挙げられる。また、セラミド3の含有量の上限としては、0.04重量%、好ましくは0.03重量%が挙げられる。 More specifically, when ceramide 1 is contained, the lower limit of the content of ceramide 1 in the composition for external use of the present invention is 0.0000001 wt%, more preferably 0.000001 wt%, still more preferably 0. 00001 weight% is mentioned. The upper limit of the content of ceramide 1 is 0.03% by weight, preferably 0.01% by weight, and more preferably 0.0001% by weight. When ceramide 2 is contained, the lower limit of the content of ceramide 2 in the composition for external use of the present invention is 0.0000005% by weight, more preferably 0.0001% by weight, more preferably 0.001% by weight, and further preferably Is 0.01% by weight. Moreover, as an upper limit of content of ceramide 2, 0.049 weight%, Preferably 0.03 weight% is mentioned. When ceramide 3 is contained, the lower limit of the content of ceramide 3 in the composition for external use of the present invention is 0.0000001 wt%, preferably 0.000001 wt%, more preferably 0.00001 wt%. Moreover, as an upper limit of content of ceramide 3, 0.04 weight%, Preferably 0.03 weight% is mentioned.
また、本発明の外用組成物において、各セラミドの比率については、特に制限されないが、例えば、以下に示す範囲が挙げられる。
セラミド1とセラミド2を組み合わせる場合:セラミド2の1重量部当たり、セラミド1が0.00001〜10000重量部、好ましくは0.00001〜100重量部、より好ましくは0.00001〜1重量部。
セラミド1とセラミド3を組み合わせる場合:セラミド1の1重量部当たり、セラミド3が0.00001〜10000重量部、好ましくは0.0001〜10000重量部、より好ましくは0.1〜1000重量部。
セラミド2とセラミド3を組み合わせる場合:セラミド2の1重量部当たり、セラミド3が0.00001〜10000重量部、好ましくは0.00001〜1000重量部、より好ましくは0.00001〜100重量部。
セラミド1とセラミド2とセラミド3を組み合わせる場合:セラミド2の1重量部当たり、セラミド1が0.00001〜10000重量部、好ましくは0.00001〜100重量部、より好ましくは0.00001〜1重量部;セラミド3が0.00001〜10000重量部、好ましくは0.00001〜1000重量部、より好ましくは0.00001〜100重量部。
Further, in the composition for external use of the present invention, the ratio of each ceramide is not particularly limited, and for example, the range shown below can be mentioned.
When ceramide 1 and ceramide 2 are combined: 0.00001 to 10000 parts by weight, preferably 0.00001 to 100 parts by weight, more preferably 0.00001 to 1 parts by weight of ceramide 1 per 1 part by weight of ceramide 2.
When ceramide 1 and ceramide 3 are combined: 0.00001 to 10000 parts by weight, preferably 0.0001 to 10000 parts by weight, more preferably 0.1 to 1000 parts by weight of ceramide 3 per 1 part by weight of ceramide 1.
When ceramide 2 and ceramide 3 are combined: 0.00001 to 10000 parts by weight, preferably 0.00001 to 1000 parts by weight, more preferably 0.00001 to 100 parts by weight of ceramide 3 per 1 part by weight of ceramide 2.
When combining ceramide 1 with ceramide 2 with ceramide 3: 0.00001 to 10000 parts by weight, preferably 0.00001 to 100 parts by weight, more preferably 0.00001 to 1 part by weight of ceramide 1 per 1 part by weight of ceramide 2 Part; 0.00001 to 10000 parts by weight, preferably 0.00001 to 1000 parts by weight, more preferably 0.00001 to 100 parts by weight of ceramide 3.
(B)高級脂肪酸
本発明の外用組成物は、高級脂肪酸を含有する。本発明の外用組成物において、高級脂肪酸は、後述する(C)〜(E)成分と共に経時的な析出物の生成抑制に寄与する。
(B) Higher Fatty Acid The composition for external use of the present invention contains higher fatty acid. In the composition for external use of the present invention, the higher fatty acid contributes to the suppression of the formation of precipitates with time together with the components (C) to (E) described later.
本発明で使用される高級脂肪酸の炭素数については、特に制限されないが、例えば、16〜20が挙げられる。セラミドの溶解性及び経時的な析出生成の抑制効果をより一層向上させるという観点から、高級脂肪酸の炭素数として、好ましくは18が挙げられる。 The carbon number of the higher fatty acid used in the present invention is not particularly limited, and, for example, 16 to 20 can be mentioned. From the viewpoint of further improving the solubility of ceramide and the inhibitory effect on the precipitation formation with time, the number of carbon atoms of the higher fatty acid is preferably 18, preferably.
また、本発明で使用される高級脂肪酸は、直鎖状又は分岐状のいずれであってもよく、また、飽和脂肪酸又は不飽和脂肪酸のいずれであってもよいが、セラミドの溶解性及び経時的な析出生成の抑制効果をより一層向上させるという観点から、分岐状又は不飽和の高級脂肪酸であることが好ましい。 Further, the higher fatty acid used in the present invention may be either linear or branched, and may be either saturated fatty acid or unsaturated fatty acid, but the solubility of ceramide and temporally It is preferable that it is a branched or unsaturated higher fatty acid from the viewpoint of further improving the suppression effect of precipitation formation.
本発明で使用される高級脂肪酸として、具体的には、ラウリン酸、ミリスチン酸、パルミチン酸、パルミトレイン酸、ステアリン酸、イソステアリン酸、オレイン酸、リノール酸、リノレイン酸、アラキドン酸、ベヘン酸、エイコサペンタエン酸、ドコサヘキサエン酸等が挙げられる。 Specific examples of the higher fatty acids used in the present invention include lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, linoleic acid, arachidonic acid, behenic acid and eicosapentaene. Examples include acids and docosahexaenoic acid.
本発明の外用組成物では、高級脂肪酸の中から1種を選択して単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 In the composition for external use of the present invention, one kind of higher fatty acids may be selected and used alone, or two or more kinds may be used in combination.
本発明で使用される高級脂肪酸として、セラミドの溶解性及び経時的な析出生成の抑制効果をより一層向上させるという観点から、好ましくは炭素数16〜20の不飽和脂肪酸又は分岐状脂肪酸、より好ましくは炭素数18の不飽和脂肪酸又は分岐状脂肪酸、更に好ましくはイソステアリン酸、オレイン酸が挙げられる。 The higher fatty acid used in the present invention is preferably an unsaturated fatty acid having 16 to 20 carbon atoms or a branched fatty acid, from the viewpoint of further improving the solubility of ceramide and the suppressing effect on precipitation formation with time. And C 18 unsaturated fatty acid or branched fatty acid, more preferably isostearic acid and oleic acid.
本発明の外用組成物において、高級脂肪酸の含有量については、特に制限されないが、例えば0.001〜0.1重量%、好ましくは0.005〜0.1重量%が挙げられる。 In the composition for external use of the present invention, the content of the higher fatty acid is not particularly limited, and for example, 0.001 to 0.1% by weight, preferably 0.005 to 0.1% by weight can be mentioned.
また、本発明の外用組成物において、セラミドと高級脂肪酸の比率については、特に制限されないが、例えば、セラミド1〜3の総量1重量部当たり、高級脂肪酸が0.01〜1000重量部、好ましくは0.1〜500重量部、より好ましくは0.5〜500重量部が挙げられる。 In the composition for external use of the present invention, the ratio of ceramide to higher fatty acid is not particularly limited, but for example, 0.01 to 1000 parts by weight of higher fatty acid is preferable, preferably 1 part by weight of ceramides 1 to 3 in total. 0.1 to 500 parts by weight, more preferably 0.5 to 500 parts by weight can be mentioned.
(C)非イオン性界面活性剤
本発明の外用組成物は、非イオン性界面活性剤を含有する。本発明の外用組成物において、非イオン性界面活性剤は、前記(B)成分並びに後述する(D)及び(E)成分と共に経時的な析出物の生成抑制に寄与する。
(C) Nonionic Surfactant The composition for external use of the present invention contains a nonionic surfactant. In the composition for external use of the present invention, the non-ionic surfactant, together with the component (B) and the components (D) and (E) described later, contributes to the suppression of the formation of precipitates with time.
本発明で使用される非イオン性界面活性剤については、薬学的又は香粧学的に許容できることを限度として特に制限されないが、経時的な析出物の生成を抑制させるという観点から、好ましくはポリオキシエチレン硬化ヒマシ油が挙げられる。 The nonionic surfactant used in the present invention is not particularly limited as far as it is pharmaceutically or cosmetically acceptable, but preferably from the viewpoint of suppressing the formation of precipitates with time. An oxyethylene hydrogenated castor oil is mentioned.
ポリオキシエチレン硬化ヒマシ油において、エチレンオキサイドの付加モル数については、特に制限されず、本発明の外用組成物では、ポリオキシエチレン硬化ヒマシ油20、ポリオキシエチレン硬化ヒマシ油30、ポリオキシエチレン硬化ヒマシ油40、ポリオキシエチレン硬化ヒマシ油50、ポリオキシエチレン硬化ヒマシ油60、ポリオキシエチレン硬化ヒマシ油70、ポリオキシエチレン硬化ヒマシ油80、ポリオキシエチレン硬化ヒマシ油90、ポリオキシエチレン硬化ヒマシ油100等のいずれを使用してもよい。これらのポリオキシエチレン硬化ヒマシ油の中でも、経時的な析出物の生成をより一層効果的に抑制させるという観点から、好ましくはポリオキシエチレン硬化ヒマシ油60が挙げられる。 In polyoxyethylene hydrogenated castor oil, the addition mole number of ethylene oxide is not particularly limited, and in the composition for external use of the present invention, polyoxyethylene hydrogenated castor oil 20, polyoxyethylene hydrogenated castor oil 30, polyoxyethylene cured Castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 70, polyoxyethylene hydrogenated castor oil 80, polyoxyethylene hydrogenated castor oil 90, polyoxyethylene hydrogenated castor oil Any of 100 or the like may be used. Among these polyoxyethylene hydrogenated castor oils, polyoxyethylene hydrogenated castor oil 60 is preferably mentioned from the viewpoint of more effectively suppressing the formation of precipitates with time.
本発明の外用組成物では、非イオン性界面活性剤の中から1種を選択して単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 In the composition for external use of the present invention, one type may be selected from nonionic surfactants and used alone, or two or more types may be used in combination.
本発明の外用組成物において、非イオン性界面活性剤の含有量については、特に制限されないが、例えば0.01〜0.5重量%、好ましくは0.01〜0.3重量%が挙げられる。 In the composition for external use of the present invention, the content of the nonionic surfactant is not particularly limited, and for example, 0.01 to 0.5% by weight, preferably 0.01 to 0.3% by weight can be mentioned. .
また、本発明の外用組成物において、セラミドと非イオン性界面活性剤の比率については、特に制限されないが、例えば、セラミド1〜3の総量1重量部当たり、非イオン性界面活性剤が1〜3000重量部、好ましくは1〜2500重量部が挙げられる。 In the composition for external use of the present invention, the ratio of ceramide to non-ionic surfactant is not particularly limited. There are 3000 parts by weight, preferably 1-2500 parts by weight.
(D)多価アルコール
本発明の外用組成物は、多価アルコールを含有する。本発明の外用組成物において、多価アルコールは、前記(B)及び(C)成分並びに後述する(E)成分と共に、経時的な析出物の生成抑制に寄与する。
(D) Polyhydric alcohol The composition for external use of the present invention contains a polyhydric alcohol. In the composition for external use of the present invention, the polyhydric alcohol, together with the components (B) and (C) and the component (E) described later, contributes to the suppression of the formation of precipitates with time.
本発明で使用される多価アルコールにおいて、水酸基の価数については、特に制限されないが、例えば2〜4価、好ましくは2〜3価が挙げられる。 In the polyhydric alcohol used in the present invention, the valence of the hydroxyl group is not particularly limited, and examples thereof include 2 to 4 valences, preferably 2 to 3 valences.
本発明で使用される多価アルコールとして、具体的には、エチレングリコール、プロピレングリコール、ブチレングリコール、ペンタンジオール、ジプロピレングリコール等の2価アルコール;グリセリン等の3価アルコール;ジグリセリン等の4価のアルコール等が挙げられる。これらの多価アルコールの中でも、好ましくはブチレングリコール、プロピレングリコール、ペンタンジオール、グリセリン、ジプロピレングリコールが挙げられる。 Specific examples of the polyhydric alcohol used in the present invention include dihydric alcohols such as ethylene glycol, propylene glycol, butylene glycol, pentanediol and dipropylene glycol; trihydric alcohols such as glycerin; and tetravalents such as diglycerin Alcohol and the like. Among these polyhydric alcohols, preferable are butylene glycol, propylene glycol, pentanediol, glycerin and dipropylene glycol.
本発明の外用組成物では多価アルコールの中から1種を選択して単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 In the composition for external use of the present invention, one type may be selected from polyhydric alcohols and used alone, or two or more types may be used in combination.
本発明の外用組成物において、多価アルコールの含有量については、特に制限されないが、例えば0.01〜30重量%、好ましくは0.1〜25重量%が挙げられる。 In the composition for external use of the present invention, the content of the polyhydric alcohol is not particularly limited, and examples thereof include 0.01 to 30% by weight, preferably 0.1 to 25% by weight.
また、本発明の外用組成物において、セラミドと多価アルコールの比率については、特に制限されないが、例えば、セラミド1〜3の総量1重量部当たり、多価アルコールが0.03〜1500000重量部、好ましくは3.3〜1250000重量部が挙げられる。 In the composition for external use of the present invention, the ratio of ceramide to polyhydric alcohol is not particularly limited, but, for example, 0.03 to 1500000 parts by weight of polyhydric alcohol per 1 part by weight of the total of ceramides 1 to 3 Preferably, 3.3 to 1250,000 parts by weight can be mentioned.
(E)クエン酸及び/又はそのアルカリ金属塩
本発明の外用組成物は、クエン酸及び/又はそのアルカリ金属塩を含有する。本発明の外用組成物において、クエン酸及び/又はそのアルカリ金属塩は、前記(B)〜(D)成分と共に経時的な析出物の生成抑制に寄与する。
(E) Citric acid and / or its alkali metal salt The composition for external use of the present invention contains citric acid and / or its alkali metal salt. In the composition for external use of the present invention, citric acid and / or its alkali metal salt, together with the components (B) to (D), contributes to the suppression of the formation of precipitates with time.
本発明で使用されるクエン酸のアルカリ金属塩としては、具体的には、クエン酸一ナトリウム、クエン酸二ナトリウム、クエン酸三ナトリウム等のクエン酸のナトリウム塩;クエン酸一カリウム、クエン酸二カリウム、クエン酸三カリウム等のクエン酸のカリウム塩等が挙げられる。 Specific examples of the alkali metal salt of citric acid used in the present invention include sodium salts of citric acid such as monosodium citrate, disodium citrate and trisodium citrate; monopotassium citrate, citric acid dibasic Examples thereof include potassium and potassium salts of citric acid such as tripotassium citrate.
また、クエン酸を使用する場合であれば、水酸化ナトリウム、水酸化カリウム等のアルカリ金属を含むアルカリを添加することによって、本発明の外用組成物のpHを調整しておくことが望ましい。 When citric acid is used, it is desirable to adjust the pH of the composition for external use of the present invention by adding an alkali containing an alkali metal such as sodium hydroxide or potassium hydroxide.
本発明の外用組成物では、クエン酸及びクエン酸のアルカリ金属の中から1種を選択して単独で使用してもよく、また2種以上を組み合わせて使用してもよい。特に、経時的な析出物の生成をより一層効果的に抑制させるという観点から、好ましくはクエン酸のアルカリ金属塩、より好ましくはクエン酸のナトリウム塩、更に好ましくはクエン酸三ナトリウムが挙げられる。 In the composition for external use of the present invention, one kind of citric acid and alkali metals of citric acid may be selected and used alone, or two or more kinds may be used in combination. In particular, an alkali metal salt of citric acid, preferably a sodium salt of citric acid, more preferably trisodium citrate is preferably used from the viewpoint of more effectively suppressing the formation of precipitates with time.
本発明の外用組成物において、クエン酸及び/又はそのアルカリ金属塩の含有量については、特に制限されないが、例えば0.001〜1重量%、好ましくは0.01〜0.6重量%が挙げられる。 In the composition for external use according to the present invention, the content of citric acid and / or its alkali metal salt is not particularly limited, but for example, 0.001 to 1% by weight, preferably 0.01 to 0.6% by weight Be
(F)水
本発明の外用組成物は、水を含有する。本発明の外用組成物において、水は基材としての役割を果たす。
(F) topical compositions of the water present invention contains water. In the composition for external use of the present invention, water serves as a substrate.
本発明の外用組成物において、水の含有量については、当該外用組成物の製剤形態等に応じて適宜設定すればよいが、例えば、50〜99.9重量%、好ましくは60〜95重量%、より好ましくは65〜90重量%が挙げられる。 In the composition for external use of the present invention, the content of water may be appropriately set according to the formulation form of the composition for external use, etc., but it is, for example, 50 to 99.9% by weight, preferably 60 to 95% by weight And more preferably 65 to 90% by weight.
その他の成分
本発明の外用組成物には、前記(A)〜(F)成分に加えて、必要に応じて、他の薬効成分を含有していてもよい。このような薬効分としては、例えば、抗ヒスタミン剤(ジフェンヒドラミン、塩酸ジフェンヒドラミン等)、局所麻酔剤(プロカイン、テトラカイン、ブピパカイン、メピパカイン、クロロプロカイン、プロパラカイン、メプリルカイン又はこれらの塩、オルソカイン、オキセサゼイン、オキシポリエントキシデカン、ロートエキス、ペルカミンパーゼ、テシットデシチン等)、抗炎症剤(インドメタシン、フェルビナク、ジクロフェナクナトリウム、ロキソプロフェンナトリウム等)、皮膚保護剤(コロジオン、ヒマシ油等)、血行促進成分(ノニル酸ワニリルアミド、ニコチン酸ベンジルエステル、カプサイシン、トウガラシエキス等)、清涼化剤(メントール、カンフル等)、ビタミン類(ビタミンA等)、ムコ多糖類(コンドロイチン硫酸ナトリウム、グルコサミン等)等が挙げられる。
Other Components In addition to the components (A) to (F), the composition for external use of the present invention may contain other pharmaceutically active ingredients as needed. Examples of such a medicinal component include antihistamines (diphenhydramine, diphenhydramine hydrochloride, etc.), local anesthetics (procaine, tetracaine, bupipakine, mepipacain, mepipacain, chlorprocaine, proparacaine, meplarchain or their salts, orthokine, oxesazein, oxypoly entoxy). Deccan, roto extract, percamine pase, tesitdecitin etc., anti-inflammatory agents (indomethacin, felbinac, diclofenac sodium, loxoprofen sodium etc.), skin protective agents (collodione, castor oil etc.) , Capsaicin, red pepper extract, etc., refreshing agent (menthol, camphor, etc.), vitamins (vitamin A, etc.), mucopolysaccharides (chondroitte Sodium sulfate, glucosamine, etc.) and the like.
また、外用組成物は、所望の製剤形態にするために、必要に応じて、その他の基材や添加剤が含まれていてもよい。このような基剤や添加剤については、薬学的に許容されることを限度として特に制限されないが、例えば、低級アルコール(エタノール、イソプロパノール等)等の水性基剤;油類(オリーブ油、サフラワー油、大豆油、つばき油、とうもろこし油、なたね油、ひまわり油、綿実油、落花生油、ラード、スクワラン、魚油等)、鉱物油(流動パラフィン、パラフィン、ゲル化炭化水素、ワセリン等)、ワックス類・ロウ類(ミツロウ、カルナウバロウ、キャンデリラロウ、セレシン、ライスワックス、マイクロクリスタリンワックス等)、エステル油(ミリスチン酸イソプロピル、アジピン酸イソプロピル、セバシン酸ジエチル、セバシン酸イソプロピル、パルミチン酸イソプロピル、パルミチン酸セチル、オレイン酸エチル等)、脂肪酸アルキルエステル、脂肪酸エステル(パルミチン酸セチル、パルミチン酸イソプロピル、リノール酸エチル等)、高級アルコール(ステアリルアルコール、セタノール、ベヘニルアルコール、ミリスチルアルコール、オレイルアルコール、ヘキサデシルアルコール、ラノリンアルコール等)、コレステロール、トリ2−エチルヘキサン酸グリセリル、2−エチルヘキサン酸セチル、シリコーンオイル(ジメチルポリシロキサン、環状シリコーン等)等の油性基剤;両性イオン性界面活性剤、陽イオン性界面活性剤、陰イオン性界面活性剤等の界面活性剤;清涼化剤(メントール、カンフル、ボルネオール、ハッカ水、ハッカ油等)、防腐剤(メチルパラベン、プロピルパラベン、安息香酸、安息香酸ナトリウム、ソルビン酸等)、着香剤(シトラール、1,8−シオネール、シトロネラール、ファルネソール等)、着色剤(タール色素(褐色201号、青色201号、黄色4号、黄色403号等)、カカオ色素、クロロフィル、酸化アルミニウム等)、粘稠剤(カルボキシビニルポリマー、ヒプロメロース、ポリビニルピロリドン、アルギン酸ナトリウム、エチルセルロース、カルボキシメチルセルロースナトリウム、キサンタンガム、カラギーナン等)、pH調整剤(リン酸、塩酸、コハク酸、酒石酸、水酸化ナトリウム、水酸化カリウム、トリエタノールアミン、トリイソプロパノールアミン等)、湿潤剤(dl−ピロリドンカルボン酸ナトリウム液、D−ソルビトール液、マクロゴール等)、安定化剤(ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、エデト酸ナトリウム、メタリン酸ナトリウム、L−アルギニン、L−アスパラギン酸、DL−アラニン、グリシン、エリソルビン酸ナトリウム、没食子酸プロピル、亜硫酸ナトリウム、二酸化硫黄、クロロゲン酸、カテキン、ローズマリー抽出物等)、酸化防止剤、紫外線吸収剤、キレート剤、粘着剤、緩衝剤、溶解補助剤、可溶化剤、保存剤等の添加剤が挙げられる。 In addition, the composition for external use may contain other base materials and additives as needed in order to obtain a desired formulation form. Such bases and additives are not particularly limited as long as they are pharmaceutically acceptable, but, for example, aqueous bases such as lower alcohols (ethanol, isopropanol etc.); oils (olive oil, safflower oil) , Soybean oil, camel oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, lard, squalane, fish oil etc., mineral oil (liquid paraffin, paraffin, gelled hydrocarbon, vaseline etc), waxes and waxes (Beeswax, carnauba wax, candelilla wax, ceresin, rice wax, microcrystalline wax, etc.), ester oil (isopropyl myristate, isopropyl adipate, diethyl sebacate, isopropyl sebacate, isopropyl palmitate, cetyl palmitate, ethyl oleate Etc), fatty acid Kyl ester, fatty acid ester (cetyl palmitate, isopropyl palmitate, ethyl linoleate, etc.), higher alcohol (stearyl alcohol, cetanol, behenyl alcohol, myristyl alcohol, oleyl alcohol, hexadecyl alcohol, lanolin alcohol etc.), cholesterol, tri-2- Oil base such as glyceryl ethylhexanoate, cetyl 2-ethylhexanoate, silicone oil (dimethylpolysiloxane, cyclic silicone etc); zwitterionic surfactant, cationic surfactant, anionic surfactant etc Surfactants; refreshing agents (menthol, camphor, borneol, peppermint water, peppermint oil etc), preservatives (methylparaben, propylparaben, benzoic acid, sodium benzoate, sorbic acid etc), flavoring agents (sit , 1,8-cionere, citronellal, farnesol etc., coloring agents (tar pigment (brown 201, blue 201, yellow 4 etc. yellow), cocoa pigment, chlorophyll, aluminum oxide etc), sticky Consisting agents (carboxyvinyl polymer, hypromellose, polyvinylpyrrolidone, sodium alginate, ethylcellulose, carboxymethylcellulose sodium, xanthan gum, carrageenan etc.), pH adjusters (phosphoric acid, hydrochloric acid, succinic acid, tartaric acid, sodium hydroxide, potassium hydroxide, trihydrate Ethanolamine, triisopropanolamine etc., wetting agent (sodium dl-pyrrolidone carboxylate solution, D-sorbitol solution, macrogol etc.), stabilizing agent (dibutylhydroxytoluene, butylhydroxyanisole, edetate nato) Sodium, sodium metaphosphate, L-arginine, L-aspartic acid, DL-alanine, glycine, sodium erythorbate, propyl gallate, sodium sulfite, sulfur dioxide, chlorogenic acid, catechin, rosemary extract, etc., antioxidants And additives such as UV absorbers, chelating agents, adhesives, buffers, solubilizers, solubilizers and preservatives.
製剤形態・用途
本発明の外用組成物の製剤形態ついては、経皮適用可能であることを限度として特に制限されず、例えば、ローション(化粧水)、ヘアローション、乳液、ボディーシャンプー、ヘアシャンプー、リンス等の液状製剤;クリーム、ジェル、軟膏等の半固形状製剤等が挙げられる。これらの中でも、好ましくは液状製剤が挙げられる。液状製剤の中でも、特にローション及びヘアローションは、乳液等と異なり、セラミドを溶解させ易くするための油分を十分量配合することが困難であり、経時的な析出物が生じ易い製剤であるにも拘わらず、高い透明性が要求される剤型である。本発明の外用組成物では、ローション及びヘアローションの製剤形態であっても、セラミドの溶解性を向上させ、経時的な析出生成を効果的に抑制することができ、製剤自体を半透明乃至透明とすることもできる。このような本発明の効果に鑑みれば、本発明の外用組成物の好適な製剤形態として、ローション及びヘアローションが挙げられる。
Dosage form and use The dosage form of the composition for external use according to the present invention is not particularly limited as long as it can be applied transdermally, for example, lotion (skin water), hair lotion, milky lotion, body shampoo, hair shampoo, rinse Liquid preparations such as: semisolid preparations such as creams, gels, and ointments. Among these, preferably liquid preparations are mentioned. Among the liquid preparations, especially lotions and hair lotions, unlike emulsions and the like, it is difficult to mix sufficient amount of oil for facilitating dissolution of ceramide, and it is a preparation which is likely to cause precipitation over time. Regardless, it is a dosage form that requires high transparency. In the composition for external use of the present invention, even in the preparation form of lotion and hair lotion, the solubility of ceramide can be improved, precipitation formation with time can be effectively suppressed, and the preparation itself is translucent to transparent. It can also be done. In view of such effects of the present invention, lotions and hair lotions can be mentioned as suitable formulation forms of the composition for external use of the present invention.
また、外用組成物は、皮膚(頭皮を含む)に適用されるものである限り、化粧料、皮膚外用医薬品、皮膚洗浄料等のいずれの製剤形態であってもよいが、好ましくは化粧料が挙げられる。 In addition, the composition for external use may be any formulation such as a cosmetic, a skin external preparation, a skin cleansing agent, etc. as long as it is applied to the skin (including the scalp), but preferably the cosmetic is It can be mentioned.
本発明の外用組成物は、前記(A)成分に基づいて角質層のバリア機能及び保湿機能を改善又は適正に維持させることができるので、保湿、肌荒れ改善、敏感肌の解消、皮膚老化の防止等のスキンケア目的で使用することができる。 The composition for external use according to the present invention can improve or properly maintain the barrier function and the moisturizing function of the stratum corneum based on the component (A), thereby improving moisturizing, roughening of the skin, elimination of sensitive skin, prevention of skin aging. Etc. can be used for skin care purposes.
製造方法
本発明の外用組成物の製造方法については、前記(A)成分を溶解させた状態で製剤化し得る限り特に制限されないが、好適な一例として、下記工程(1)〜(3)を経て製造する方法が挙げられる。
工程(1): (A)成分の全量、(B)成分の全量、(C)成分の全量、(D)成分の一部、及び必要に応じて添加される他の成分の中で親油性のものを混合した後に、90〜130℃程度に加熱して溶解させ、一次組成物を得る。当該工程(1)において、(D)成分の添加量については、最終の外用組成物での0.05〜1重量%、好ましくは0.1〜1重量%程度に相当する量であればよい。
工程(2): 前記工程(1)で得られた一次組成物を90〜130℃程度に加熱した状態で、撹拌しながら90℃以上に加熱した(F)成分の一部を徐々に添加して二次組成物を得る。当該工程(2)において、(F)成分の添加量については、最終の外用組成物での0.1〜45重量%、好ましくは0.1〜30重量%、より好ましくは0.1〜10重量%、更に好ましくは0.1〜5重量%程度に相当する量であればよい。
工程(3): 前記工程(2)で得られた二次組成物を40℃程度以下に冷却した後に、(D)成分の残部、(E)成分の全量、(F)成分の残部、及び必要に応じて添加されるその他の成分の中で親水性のものを添加して混合することにより、本発明の外用組成物を得る。当該工程(3)において、二次組成物の冷却は、室温の(F)成分の一部を添加することによって行ってもよい。
Production method The production method of the composition for external use of the present invention is not particularly limited as long as it can be formulated in a state in which the component (A) is dissolved, but as a suitable example, through the following steps (1) to (3) The method of manufacturing is mentioned.
Step (1): The total amount of component (A), the total amount of component (B), the total amount of component (C), part of component (D), and lipophilicity among other components added as needed The mixture is heated and dissolved at about 90.degree. To 130.degree. C. to obtain a primary composition. In the step (1), the addition amount of the component (D) may be an amount corresponding to about 0.05 to 1% by weight, preferably about 0.1 to 1% by weight, in the final composition for external use .
Step (2): While heating the primary composition obtained in the above step (1) to about 90 to 130 ° C., gradually add a part of the component (F) heated to 90 ° C. or higher while stirring To obtain a secondary composition. In the step (2), the addition amount of the component (F) is 0.1 to 45% by weight, preferably 0.1 to 30% by weight, more preferably 0.1 to 10% by weight of the final composition for external use. It may be an amount corresponding to about% by weight, more preferably about 0.1 to 5% by weight.
Step (3): After the secondary composition obtained in the step (2) is cooled to about 40 ° C. or less, the remainder of the component (D), the total amount of the component (E), the remainder of the component (F), and The external use composition of the present invention is obtained by adding and mixing hydrophilic ones among other components added as needed. In the said process (3), cooling of a secondary composition may be performed by adding a part of (F) component of room temperature.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。なお、以下の実施例及び比較例において、セラミド1はN−(27−ステアロイルオキシヘプタコサノイル)フィトスフィンゴシン(商品名「CERAMIDEI
」、エボニックジャパン株式会社)、セラミド2はステアロイルジヒドロスフィンゴシン(商品名「セラミド TIC−001」高砂香料工業株式会社)、セラミド3はステアロイルフィトスフィンゴシン(商品名「CERAMIDEIII」、エボニックジャパン株式会社)を使用した。
EXAMPLES The present invention will be more specifically described below by way of Examples, but the present invention is not limited thereto. In the following Examples and Comparative Examples, ceramide 1 is N- (27-stearoyloxyheptacosanoyl) phytosphingosine (trade name "CERAMIDEI
"Evonik Japan Co., Ltd.", Ceramide 2 uses stearoyl dihydrosphingosine (trade name "Ceramide TIC-001" Takasago Flavor Industrial Co., Ltd.), and Ceramide 3 uses stearoyl phytosphingosine (trade name "CERAMIDE III", Evonik Japan Co., Ltd.) did.
実施例1〜23
表1〜4に示す組成の外用組成物(ローション)を製造した。具体的な製造方法は、以下に示す通りである。
Examples 1 to 23
The external composition (lotion) of the composition shown to Tables 1-4 was manufactured. The specific manufacturing method is as follows.
先ず、セラミド(セラミド1〜3)の全量、イソステアリン酸又はオレイン酸の全量、以下に示す多価アルコールの所定量、及びポリオキシエチレン硬化ヒマシ油60の全量を混合し、120℃に加熱して溶解させ、一次組成物を得た。
(一次組成物に添加した多価アルコールの種類と量)
実施例1〜19、23、26、27及び32:ブチレングリコール(最終の外用組成物で0.1重量%に相当する量)、
実施例21及び24:ジプロピレングリコール(最終の外用組成物で0.1重量%に相当する量)
実施例20、25及び29:プロピレングリコール(最終の外用組成物で0.1重量%に相当する量)
実施例22及び28:グリセリン(最終の外用組成物で0.1重量%に相当する量)、
実施例30:ブチレングリコール(最終の外用組成物で1重量%に相当する量)
実施例31:グリセリン(最終の外用組成物で1重量%に相当する量)
First, the total amount of ceramide (ceramides 1 to 3), the total amount of isostearic acid or oleic acid, the predetermined amount of polyhydric alcohol shown below, and the total amount of polyoxyethylene hydrogenated castor oil 60 are mixed and heated to 120 ° C. Dissolve to obtain a primary composition.
(Type and amount of polyhydric alcohol added to primary composition)
Examples 1-19, 23, 26, 27 and 32: butylene glycol (the amount corresponding to 0.1% by weight in the final external composition),
Examples 21 and 24: Dipropylene glycol (amount corresponding to 0.1% by weight in the final external composition)
Examples 20, 25 and 29: Propylene glycol (the amount corresponding to 0.1% by weight in the final external composition)
Examples 22 and 28: Glycerin (amount corresponding to 0.1% by weight in the final composition for external use),
Example 30: butylene glycol (amount corresponding to 1% by weight in the final composition for external use)
Example 31: Glycerin (the amount corresponding to 1% by weight in the final composition for external use)
次いで、得られた一次組成物を120℃に加熱した状態で、90℃に加温した精製水の一部(最終の外用組成物で約0.35重量%に相当する量)を徐々に添加して、二次組成物を得た。得られた二次組成物を100℃以上の状態で、室温の精製水の一部(最終の外用組成物で約0.5重量%に相当する量)を加え、室温にまで冷却した後に、多価アルコールの残部、クエン酸三ナトリウムの全量(実施例1〜31の場合)、クエン酸と水酸化ナトリウムの全量(実施例32の場合)、フェノキシエタノールの全量(実施例1〜26、31、及び32の場合)、及び精製水の残部を混合した混合液を添加することによって、外用組成物(ローション)を製造した。 Next, while heating the obtained primary composition to 120 ° C., gradually add a portion of purified water heated to 90 ° C. (an amount corresponding to about 0.35% by weight in the final composition for external use) The secondary composition was obtained. A portion of the purified water at room temperature (corresponding to about 0.5% by weight of the final external composition) is added to the obtained secondary composition at 100 ° C. or higher, and cooled to room temperature. The balance of polyhydric alcohol, the total amount of trisodium citrate (in the case of Examples 1 to 31), the total amount of citric acid and sodium hydroxide (in the case of Example 32), the total amount of phenoxyethanol (Examples 1 to 26, 31, And 32) and a mixture of the rest of purified water was added to produce a composition for external use (lotion).
得られた各外用組成物を遮光条件下で室温にて5日間静置した後に、析出生成の有無を目視にて確認し、以下の判定基準に従って保存後の析出生成の程度を評価した。
<保存後の析出物の生成の程度の判定基準>
◎:析出物の生成が全く認められない。
○:析出物の生成が極めて微量認められるが、実用上は問題にならない。
△:析出物の生成が実用上問題になる程度に認められるが、析出物の生成量は多くはない。
×:多くの析出物の生成が認められる。
××:顕著に多い析出物の生成が認められる。
After each obtained composition for external use was allowed to stand at room temperature for 5 days under light shielding conditions, the presence or absence of precipitation was visually confirmed, and the degree of precipitation after storage was evaluated according to the following judgment criteria.
<Criteria for determining the degree of formation of precipitates after storage>
◎: no formation of precipitates observed
○: The formation of a very small amount of precipitates is recognized, but this is not a problem in practical use.
Δ: The formation of precipitates is recognized to be a problem in practical use, but the amount of precipitates formed is not large.
X: The formation of many precipitates is recognized.
××: Remarkable formation of precipitates is observed.
得られた結果を表1〜4示す。これらの結果から、セラミド1〜3の中で2種以上と水を含む外用組成物において、高級脂肪酸(イソステアリン酸又はオレイン酸)、非イオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油60)、多価アルコール(ブチレングリコール、ペンタンジオール、プロピレングリコール、ジプロピレングリコール、グリセリン)、並びにクエン酸及び/又はそのアルカリ金属塩(クエン酸又はクエン酸三ナトリウム)を含有させることによって、経時的な析出物の生成を抑制でき、優れた製剤安定性を備え得ることが確認された。特に、実施例16〜32の外用組成物では、セラミド1〜3の3種のセラミドを組み合わせた場合でも、経時的な析出物の生成を抑制できており、格段に優れた製剤安定性の向上が認められた。また、実施例のいずれの外用組成物も透明で、外観に優れるものであった。 Tables 1 to 4 show the obtained results. From these results, in the externally applied composition containing two or more of ceramides 1 to 3 and water, higher fatty acid (isostearic acid or oleic acid), nonionic surfactant (polyoxyethylene hardened castor oil 60), Precipitation over time by incorporating polyhydric alcohol (butylene glycol, pentanediol, propylene glycol, dipropylene glycol, glycerin) and citric acid and / or alkali metal salt thereof (citric acid or trisodium citrate) It has been confirmed that it is possible to suppress the formation of and to provide excellent formulation stability. In particular, in the compositions for external use of Examples 16 to 32, even when three kinds of ceramides of ceramides 1 to 3 are combined, the formation of precipitates with time can be suppressed, and the preparation stability is remarkably improved. Was recognized. Moreover, all the compositions for external use of the Example were transparent, and were excellent in the external appearance.
参考例1〜3及び比較例1〜16
表5〜7に示す組成の外用組成物(ローション)を前記実施例と同様の方法で製造し、前記実施例1と同様の方法で保存後の析出生成の程度を評価した。
Reference Examples 1 to 3 and Comparative Examples 1 to 16
The composition for external use (lotion) of the composition shown to Tables 5-7 was manufactured by the method similar to the said Example, and the grade of precipitation formation after storage was evaluated by the method similar to the said Example 1. FIG.
得られた結果を表5〜7に示す。参考例1〜3から明らかなように、セラミド1〜3の1種のみを含む外用組成物では、クエン酸三ナトリウムを配合しなくても、経時的な析出物の生成は認められなかった。即ち、セラミドを含む外用組成物において、経時的な析出物の生成は、セラミド1〜3の中で2種以上を併用する場合に特有の課題であることが確認された。 The obtained results are shown in Tables 5-7. As apparent from Reference Examples 1 to 3, in the externally applied composition containing only one of ceramides 1 to 3, formation of precipitates with time was not observed even if trisodium citrate was not blended. That is, in the composition for external use containing ceramide, it was confirmed that the formation of precipitates with time is a unique problem when two or more of ceramides 1 to 3 are used in combination.
また、比較例1〜10から明らかなように、セラミド1〜3の中で2種以上と水を含む外用組成物において、高級脂肪酸(イソステアリン酸)、非イオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油60)、及び多価アルコール(ブチレングリコール、ペンタンジオール、及びグリセリン)を含んでいても、クエン酸及び/又はその塩を含んでいない場合には、経時的な析出物の生成が認められ、十分な製剤安定性を備えることができなかった。更に、比較例11〜14から、クエン酸及び/又はその塩に代えて、他の有機酸の塩(酒石酸ナトリウム、グルコン酸ナトリウム、乳酸ナトリウム、及びピロリドンカルボン酸ナトリウム)を使用しても、経時的な析出物の生成を抑制できないことも確認された。 Further, as apparent from Comparative Examples 1 to 10, in an external composition containing two or more of ceramides 1 to 3 and water, a higher fatty acid (isostearic acid), a nonionic surfactant (polyoxyethylene cured) Even if it contains castor oil 60) and polyhydric alcohols (butylene glycol, pentanediol, and glycerin), but does not contain citric acid and / or a salt thereof, formation of precipitates over time is observed. And could not provide sufficient formulation stability. Furthermore, even if salts of other organic acids (sodium tartrate, sodium gluconate, sodium lactate and sodium pyrrolidonecarboxylate) are used in place of citric acid and / or salts thereof from Comparative Examples 11 to 14 It was also confirmed that the formation of specific precipitates could not be suppressed.
更に、比較例15及び16から、高級脂肪酸(イソステアリン酸)及び非イオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油60)のいずれか一方を欠いた場合でも、経時的な析出物の生成を抑制できないことも確認された。 Furthermore, according to Comparative Examples 15 and 16, even when any one of higher fatty acid (isostearic acid) and nonionic surfactant (polyoxyethylene hydrogenated castor oil 60) is lacking, the formation of precipitates with time is suppressed. It was also confirmed that it could not be done.
以上の結果から、前記実施例1〜32において認められた経時的な析出物の生成抑制は、セラミド1〜3の中で2種以上と水を含む外用組成物において、高級脂肪酸、非イオン性界面活性剤、多価アルコール、並びにクエン酸及び/又はそのアルカリ金属塩を一体として含むことによって獲得される効果であることが確認された。 From the above results, the suppression of the formation of precipitates with time observed in Examples 1 to 32 is higher fatty acid and nonionic in the composition for external use containing two or more kinds of ceramides 1 to 3 and water. It has been confirmed that this is an effect obtained by integrally containing a surfactant, a polyhydric alcohol, and citric acid and / or an alkali metal salt thereof.
製剤例1〜8:ローション(化粧水)
表8に示す組成の外用組成物(ローション)を以下の方法に従って製造した。
Formulation Examples 1 to 8: Lotion
An external composition (lotion) having a composition shown in Table 8 was produced according to the following method.
先ず、セラミド(セラミド1〜3)の全量、イソステアリン酸又はオレイン酸の全量、以下に示す多価アルコールの所定量、及びポリオキシエチレン硬化ヒマシ油60の全量を混合し、120℃に加熱して溶解させ、一次組成物を得た。
(一次組成物に添加した多価アルコールの種類と量)
製剤例1及び2:グリセリン(最終の外用組成物で0.1重量%に相当する量)
製剤例3:グリセリン(最終の外用組成物で0.5重量%に相当する量)
製剤造例4〜7:ブチレングリコール(最終の外用組成物で0.1重量%に相当する量)
製剤例8:ブチレングリコール(最終の外用組成物で1重量%に相当する量)
First, the total amount of ceramide (ceramides 1 to 3), the total amount of isostearic acid or oleic acid, the predetermined amount of polyhydric alcohol shown below, and the total amount of polyoxyethylene hydrogenated castor oil 60 are mixed and heated to 120 ° C. Dissolve to obtain a primary composition.
(Type and amount of polyhydric alcohol added to primary composition)
Formulation Examples 1 and 2: Glycerin (amount corresponding to 0.1% by weight in the final composition for external use)
Formulation Example 3: Glycerin (amount corresponding to 0.5% by weight in the final composition for external use)
Preparations 4 to 7: butylene glycol (equivalent to 0.1% by weight in the final composition for external use)
Formulation Example 8: butylene glycol (an amount corresponding to 1% by weight in the final external composition)
次いで、得られた一次組成物を120℃に加熱した状態で、90℃に加温した精製水の一部(最終の外用組成物で0.35重量%に相当する量)を徐々に添加して、二次組成物を得た。得られた二次組成物を100℃以上の状態で、室温の精製水の一部(最終の外用組成物で約0.5重量%に相当する量)を加え、室温にまで冷却した。その後、多価アルコールの残部、クエン酸三ナトリウムの全量、メチルグルセス−20の全量、ポリアクリル酸ナトリウムの全量、フェノキシエタノールの全量、及び精製水の残部を混合した混合液を添加することによって、外用組成物(ローション)を製造した。 Then, while heating the obtained primary composition to 120 ° C., gradually add a portion of purified water heated to 90 ° C. (the amount corresponding to 0.35% by weight in the final external composition) The secondary composition was obtained. A portion of purified water at room temperature (an amount corresponding to about 0.5% by weight of the final external composition) was added to the obtained secondary composition at 100 ° C. or higher, and cooled to room temperature. Thereafter, the composition for external use is added by adding a mixed solution in which the remaining portion of polyhydric alcohol, the total amount of trisodium citrate, the total amount of methylcelluloses -20, the total amount of sodium polyacrylate, the total amount of phenoxyethanol and the remaining portion of purified water Product (lotion) was manufactured.
得られた外用組成物は、いずれも、前記実施例の場合と同様に、経時的な析出物の生成を抑制できることが確認された。 It was confirmed that all of the obtained compositions for external use can suppress the formation of precipitates with time as in the case of the above examples.
製剤例9:ジェル状化粧水
表9に示す組成の外用組成物(ジェル状化粧水)を以下の方法に従って製造した。
Formulation Example 9 Gel-like Lotion A composition for external use (gel-like lotion) having a composition shown in Table 9 was produced according to the following method.
先ず、セラミド(セラミド1〜3)の全量、イソステアリン酸の全量、ブチレングリコールの一部(最終の外用組成物で0.1重量%に相当する量)、及びポリオキシエチレン硬化ヒマシ油60の全量を混合し、120℃に加熱して溶解させ、一次組成物を得た。 First, the total amount of ceramide (ceramides 1 to 3), the total amount of isostearic acid, a part of butylene glycol (an amount corresponding to 0.1% by weight in the final external composition), and the total amount of polyoxyethylene hydrogenated castor oil 60 The mixture was mixed and heated to 120.degree. C. to dissolve to obtain a primary composition.
次いで、得られた一次組成物を120℃に加熱した状態で、90℃に加温した精製水の一部(最終の外用組成物で0.35重量%に相当する量)を徐々に添加して、二次組成物を得た。得られた二次組成物を100℃以上の状態で、室温の精製水の一部(最終の外用組成物で約0.5重量%に相当する量)を加え、室温にまで冷却した。その後、多価アルコールの残部、クエン酸三ナトリウムの全量、ヒドロキシエチルセルロースの全量、カルボマーの全量、アルギン酸ナトリウムの全量、メチルパラベンの全量、ポリクオタニウム−51の全量、ポリクオタニウム−61の全量、ベタインの全量、及び精製水の残部を混合して溶解させた溶解液を40℃の状態で添加、混合した後に、室温まで冷却することによって、外用組成物(ジェル状化粧水)を製造した。 Then, while heating the obtained primary composition to 120 ° C., gradually add a portion of purified water heated to 90 ° C. (the amount corresponding to 0.35% by weight in the final external composition) The secondary composition was obtained. A portion of purified water at room temperature (an amount corresponding to about 0.5% by weight of the final external composition) was added to the obtained secondary composition at 100 ° C. or higher, and cooled to room temperature. Thereafter, the remaining portion of polyhydric alcohol, the total amount of trisodium citrate, the total amount of hydroxyethylcellulose, the total amount of carbomer, the total amount of sodium alginate, the total amount of methylparaben, the total amount of polyquaternium-51, the total amount of polyquaternium-61, the total amount of betaine, A solution obtained by mixing and dissolving the rest of the purified water was added at 40 ° C., mixed, and cooled to room temperature to produce an external composition (gel-like lotion).
得られた外用組成物は、前記実施例の場合と同様に、経時的な析出物の生成を抑制できることが確認された。 It was confirmed that the composition for external use obtained can suppress the formation of precipitates with time, as in the case of the above-mentioned examples.
製剤例10:育毛ローション
表10に示す組成の外用組成物(育毛ローション)を以下の方法に従って製造した。
Formulation Example 10 Hair Growth Lotion An external composition (hair growth lotion) having a composition shown in Table 10 was produced according to the following method.
先ず、セラミド(セラミド1〜3)の全量、オレイン酸の全量、プロピレングリコールの全量、及びポリオキシエチレン硬化ヒマシ油60の全量を混合し、120℃に加熱して溶解させ、一次組成物を得た。 First, the total amount of ceramide (ceramides 1 to 3), the total amount of oleic acid, the total amount of propylene glycol, and the total amount of polyoxyethylene hydrogenated castor oil 60 are mixed, heated to 120 ° C. and dissolved to obtain a primary composition. The
次いで、得られた一次組成物を120℃に加熱した状態で、90℃に加温した精製水の一部(最終の外用組成物で0.15重量%に相当する量)を徐々に添加して、二次組成物を得た。得られた二次組成物を100℃以上の状態で、室温の精製水の一部(最終の外用組成物で約0.5量%に相当する量)を加え、室温にまで冷却した。その後、クエン酸三ナトリウムの全量、エタノールの全量、β−グリチルレチン酸の全量、ヒノキチオールの全量、酢酸DL−α−トコフェロールの全量、ピリドキシン塩酸塩の全量、センブリ抽出液の全量、アロエエキスの全量、l−メントールの全量、及び精製水の残部を混合した混合液を添加することによって、外用組成物(育毛ローション)を製造した。 Then, while heating the obtained primary composition to 120 ° C., gradually add a portion of purified water heated to 90 ° C. (the amount corresponding to 0.15% by weight in the final external composition) The secondary composition was obtained. A portion of the purified water at room temperature (an amount corresponding to about 0.5% by volume of the final external composition) was added to the obtained secondary composition at 100 ° C. or higher, and cooled to room temperature. Thereafter, the total amount of trisodium citrate, the total amount of ethanol, the total amount of β-glycyrrhetinic acid, the total amount of hinokitiol, the total amount of DL-α-tocopherol acetate, the total amount of pyridoxine hydrochloride, the total amount of cerebrus extract, the total amount of aloe extract, The composition for external use (hair growth lotion) was manufactured by adding the liquid mixture which mixed the whole part of l-menthol and the remainder of purified water.
得られた外用組成物は、前記実施例の場合と同様に、経時的な析出物の生成を抑制できることが確認された。 It was confirmed that the composition for external use obtained can suppress the formation of precipitates with time, as in the case of the above-mentioned examples.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014171807A JP6522908B2 (en) | 2014-08-26 | 2014-08-26 | Composition for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014171807A JP6522908B2 (en) | 2014-08-26 | 2014-08-26 | Composition for external use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016044167A JP2016044167A (en) | 2016-04-04 |
JP6522908B2 true JP6522908B2 (en) | 2019-05-29 |
Family
ID=55635049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014171807A Active JP6522908B2 (en) | 2014-08-26 | 2014-08-26 | Composition for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6522908B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102565630B1 (en) * | 2016-04-14 | 2023-08-10 | 주식회사 엘지생활건강 | Cosmetic composition containing phenoxyethanol |
JP6988574B2 (en) * | 2018-03-01 | 2022-01-05 | 日油株式会社 | Aqueous gel cosmetic |
WO2020175700A1 (en) * | 2019-02-28 | 2020-09-03 | 株式会社日本触媒 | Aqueous dispersion for cosmetic preparations, cosmetic composition and method for producing cosmetic preparation |
WO2020230691A1 (en) * | 2019-05-10 | 2020-11-19 | 株式会社アルビオン | Composition containing ceramide and isobutyl oleate |
JP2020203862A (en) * | 2019-06-18 | 2020-12-24 | 小林製薬株式会社 | External composition for improving skin barrier function |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200413020A (en) * | 2002-07-05 | 2004-08-01 | Kose Corp | Vesicle dispersion and cosmetic containing the same |
PL2051691T3 (en) * | 2006-10-13 | 2010-10-29 | Evonik Degussa Gmbh | Skin treatment composition |
JP5455292B2 (en) * | 2007-06-15 | 2014-03-26 | 小林製薬株式会社 | Skin external composition |
US20110224310A1 (en) * | 2008-11-21 | 2011-09-15 | Fujifilm Corporation | Ceramide dispersion and method for producing same |
-
2014
- 2014-08-26 JP JP2014171807A patent/JP6522908B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016044167A (en) | 2016-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12053547B2 (en) | Liposomal compositions and methods of use | |
JP3609834B2 (en) | Skin preparation | |
JP3991063B2 (en) | Topical skin preparation | |
JP6522908B2 (en) | Composition for external use | |
JP4989119B2 (en) | Skin external preparation suitable for vesicle system | |
JP6377381B2 (en) | Liposome composition | |
JP5342736B2 (en) | Oil-in-water emulsion and method for producing the same | |
TW201513853A (en) | Formulations for epidermal repair and treatment of dermatological diseases and disorders | |
JP2016130224A (en) | External composition | |
JP6426363B2 (en) | Oil-in-water emulsion composition | |
JP4778256B2 (en) | Oil-in-water emulsion and method for producing the same | |
JP6376835B2 (en) | Topical skin preparation | |
JPS6115809A (en) | Cell activator | |
JP2001233754A (en) | Emulsion type skin care preparation | |
JP5645302B2 (en) | Pharmaceutical emulsion for external use | |
JP6747763B2 (en) | Emulsified cosmetics | |
TWI772333B (en) | Composition containing linoleic acid | |
JP7446711B2 (en) | Skin external composition | |
JP2016188187A (en) | External pharmaceutical composition | |
JP2019112336A (en) | Water-in-oil emulsion composition | |
JPH10279417A (en) | Preparation for external use for skin | |
JP6419661B2 (en) | Skin external preparation composition and skin external preparation containing the skin external preparation composition | |
WO2018123003A1 (en) | Topical composition for suppressing melanogenesis | |
JP2003238383A (en) | Skin care preparation | |
WO2018123004A1 (en) | Topical composition for suppressing melanogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170728 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190425 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6522908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |